97 related articles for article (PubMed ID: 10612090)
1. [Immunological markers of disease activity in the course of 2-CDA treatment of multiple sclerosis].
Michałowska-Wender G; Tokarz-Kupczyk E; Losy J; Sniatała-Kamasa M; Wender M
Neurol Neurochir Pol; 1999; 33(4):749-56. PubMed ID: 10612090
[TBL] [Abstract][Full Text] [Related]
2. Activity and toxicity of 2-CDA in Langerhans cell histiocytosis: a single institutional experience.
Biswas G; Khadwal A; Arora B; Bhagwat R; Banavali SD; Nair CN; Pai SK; Kurkure PA; Parikh PM
Indian J Cancer; 2007; 44(4):137-41. PubMed ID: 18322355
[TBL] [Abstract][Full Text] [Related]
3. Splenic lymphoma with villous lymphocytes (SLVL) responding to 2-chlorodeoxyadenosine (2-CdA).
Virchis A; Mehta A
Br J Haematol; 1998 Mar; 100(3):609. PubMed ID: 9504654
[No Abstract] [Full Text] [Related]
4. Successful treatment of warm antibody (IgG/C3 positive) autoimmune hemolytic anemia in hairy-cell leukemia with 2-CdA in the elderly.
Viens D; St-Hilaire E; Beauregard P; Dufresne J; Knecht H
Leuk Lymphoma; 2008 Jul; 49(7):1424-6. PubMed ID: 18452105
[No Abstract] [Full Text] [Related]
5. 2-CdA in the treatment of hairy cell leukaemia.
Abhyankar D; Bajpai S; Saikia T; Gopal R; Nair CN; Advani SH
J Assoc Physicians India; 2001 Aug; 49():785-7. PubMed ID: 11837464
[TBL] [Abstract][Full Text] [Related]
6. The tumor necrosis factor family and and correlation with disease activity and response to treatment in hairy cell leukemia.
Barak V; Nisman B; Polliack A
Eur J Haematol; 1999 Feb; 62(2):71-5. PubMed ID: 10052708
[TBL] [Abstract][Full Text] [Related]
7. 2-chlorodeoxyadenosine (2-CdA) does not change the expression of Fas antigen on chronic lymphocytic leukaemia cells.
Gora-Tybor J; Lech-Miranda E; Blonski JZ; Robak T
Adv Exp Med Biol; 2000; 486():307-10. PubMed ID: 11783506
[No Abstract] [Full Text] [Related]
8. Low dose 2-CdA schedule activity in splenic marginal zone lymphomas.
Riccioni R; Caracciolo F; Galimberti S; Cecconi N; Petrini M
Hematol Oncol; 2003 Dec; 21(4):163-8. PubMed ID: 14735554
[TBL] [Abstract][Full Text] [Related]
9. [The effect of large dose prednisone therapy on immunological markers in multiple sclerosis].
Wender M; Losy J; Michałowska-Wender G; Kozubski W; Sosnowski P
Neurol Neurochir Pol; 1999; 33(4):771-9. PubMed ID: 10612092
[TBL] [Abstract][Full Text] [Related]
10. Hairy cell leukemia: evaluation of the long-term outcome in 121 patients.
Zinzani PL; Pellegrini C; Stefoni V; Derenzini E; Gandolfi L; Broccoli A; Argnani L; Quirini F; Pileri S; Baccarani M
Cancer; 2010 Oct; 116(20):4788-92. PubMed ID: 20597132
[TBL] [Abstract][Full Text] [Related]
11. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia.
Santana VM; Mirro J; Kearns C; Schell MJ; Crom W; Blakley RL
J Clin Oncol; 1992 Mar; 10(3):364-70. PubMed ID: 1346800
[TBL] [Abstract][Full Text] [Related]
12. 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society.
Weitzman S; Braier J; Donadieu J; Egeler RM; Grois N; Ladisch S; Pötschger U; Webb D; Whitlock J; Arceci RJ
Pediatr Blood Cancer; 2009 Dec; 53(7):1271-6. PubMed ID: 19731321
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil for severe autoimmune haemolytic anemia.
Zimmer-Molsberger B; Knauf W; Thiel E
Lancet; 1997 Oct; 350(9083):1003-4. PubMed ID: 9329520
[No Abstract] [Full Text] [Related]
14. Correlation of serum levels of interleukin-1 family members with disease activity and response to treatment in hairy cell leukemia.
Barak V; Nisman B; Polliack A; Vannier E; Dinarello CA
Eur Cytokine Netw; 1998 Mar; 9(1):33-9. PubMed ID: 9613675
[TBL] [Abstract][Full Text] [Related]
15. Bilateral facial nerve palsy as first indication of relapsing hairy cell leukemia after 36 years.
Ferrari J; Lang W; Thurnher S; Müllauer L; Raderer M
Neurology; 2004 Jul; 63(2):399-400. PubMed ID: 15277655
[No Abstract] [Full Text] [Related]
16. 2-chloro-2'-deoxyadenosine: clinical applications in hematology.
Delannoy A
Blood Rev; 1996 Sep; 10(3):148-66. PubMed ID: 8932828
[TBL] [Abstract][Full Text] [Related]
17. Determination of 2-chloro-2'-deoxyadenosine in human plasma.
Liliemark J; Pettersson B; Juliusson G
Biomed Chromatogr; 1991 Nov; 5(6):262-4. PubMed ID: 1684727
[TBL] [Abstract][Full Text] [Related]
18. 2-Chlorodeoxyadenosine in the treatment of multiple myeloma.
Dimopoulos MA; Kantarjian HM; Estey EH; Alexanian R
Blood; 1992 Sep; 80(6):1626. PubMed ID: 1355673
[No Abstract] [Full Text] [Related]
19. [2-CDA in treatment of hairy cell leukemia: a comparison between intravenous and subcutaneous administration. Swiss Study Group of Applied Cancer Research].
Sperb RA; von Rohr A; Ratschiller D; Bacchi M; Tichelli A; Hess U; Cerny T; Tobler A; Betticher DC
Schweiz Med Wochenschr; 1998 Oct; 128(42):1593-7. PubMed ID: 9824888
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a.
Perini P; Tiberio M; Sivieri S; Facchinetti A; Biasi G; Gallo P
Eur Cytokine Netw; 2000 Mar; 11(1):81-6. PubMed ID: 10705303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
